Case 004 — induction at home, COWS < 4.

Encounter summary

Member is a 34-year-old union electrician, four-year history of opioid use disorder, currently on a daily fentanyl-pressed-pill habit (eight to twelve "M30" counterfeit pills per day, illicitly purchased). Two years prior, attempted in-office buprenorphine induction at a community clinic in Hibbing; experienced severe precipitated withdrawal at the second 4-mg dose, left the clinic against medical advice, returned to use within hours. Has carried the experience forward as the reason "this medication doesn't work for me." It does. The protocol that didn't work was the protocol from before the fentanyl-dominant drug supply made it largely unworkable.

The framework for this attempt: a low-dose home induction, sometimes called a "Bernese-style" or "microdose" induction¹, in which buprenorphine is started at sub-therapeutic doses (0.5 mg) while the member continues their existing opioid use and titrates upward over five to seven days, rather than requiring abstinence and waiting for the COWS score to climb before the first dose. The protocol is increasingly the default for fentanyl-dominant inductions, supported by the SAMHSA TIP-63, the Boston Medical Center protocol library, and a growing literature in JAMA Internal Medicine and Drug and Alcohol Dependence².

Splits

Split	Day	Event	Bup dose	COWS
00:00	D-7	Visit 1; protocol explained; low-dose strips dispensed	—	—
00:24	D01	0.5 mg sublingual; continued use of fentanyl unchanged	0.5 mg	—
00:48	D02	0.5 mg AM, 0.5 mg PM	1.0 mg	—
01:24	D03	1 mg AM, 1 mg PM	2.0 mg	—
01:96	D04	2 mg AM, 2 mg PM	4.0 mg	—
02:24	D05	4 mg AM, 4 mg PM	8.0 mg	2/48
03:00	D06	Member discontinues fentanyl; bup 8/2 mg AM	8.0 mg	3/48
03:24	D07	Phone check-in; sleep restored	8.0 mg	2/48
04:00	W02	Visit 2; bup titrated to 16 mg total daily	16.0 mg	1/48
06:00	W06	Visit 3; member working full schedule, no return-to-use	16.0 mg	0/48

Debrief — what was tracking

The protocol worked the way the literature said it would. The COWS never reached 5. The member never experienced the precipitated-withdrawal storm that defined their prior attempt. The cross-over from fentanyl to buprenorphine happened on day six and was, in their description, "anticlimactic" — a gentle decline of the fentanyl craving rather than the kicking-in-a-blanket withdrawal they had braced for. Sleep was the first thing to recover; appetite and concentration followed inside of two weeks. By week six the member had returned to a full work schedule.

What we did not do that we used to do: require an in-office observation period for the first dose. The home-induction literature has now become large enough and the clinical experience clear enough that we don't add the friction of an office visit at the first 0.5-mg dose. We saw the member at days 7 and 14; we phoned them every other day in the first week; we were available by SMS. They had every dose, every dose's window, and our cell number on a printed sheet that traveled in their wallet.

What didn't track

The work conversation. The member is a union electrician with a 5-year DOT license requirement; the question of how a buprenorphine prescription interacts with the DOT testing program is unresolved at the federal level³ and resolved-in-practice differently by different employers. We worked the conversation with the member and an employee-assistance program counselor; the member chose to disclose. The disclosure did not cost them their job. We do not generalize from one case.

Plan, T+0

• Maintain buprenorphine 16 mg total daily (8/2 AM, 8/2 PM).
• Visit cadence: monthly through month 3, then every six weeks if stable.
• Hepatitis A, B, and C testing per CDC guidance; HCV antibody and confirm by PCR if positive.
• Therapy referral offered (member declined). Re-offer at month 3 and month 6.
• Naloxone (4 mg intranasal, 2 doses) dispensed at each refill. Family member trained.

What this case is and isn't

This is one induction. The literature on home induction protocols is consistent enough that we have made it our default for fentanyl-dominant cases, but every member arrives in a different starting state and the protocol's dose window is calibrated to their use. This is also a case in which a prior bad experience with the medication had become a barrier to care for two years. The single most consequential thing the practice did was to take that prior experience seriously, name it, and offer a different protocol — not a re-attempt of the same one with more encouragement. The protocol is the protocol. The member did the work.